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Abstract
Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients
with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a
sustained virologic response (SVR) defined as “undetectable” Hepatitis C Virus (HCV) RNA in the serum or plasma at
12 to 24 weeks following the end of treatment.
HCV RNA viral load (VL) monitoring is used to guide treatment duration where decisions can be made on-therapy
and to determine whether or not to stop therapy. In addition, clinicians determine treatment regimen and
duration based on the HCV genotype (1-6) as well as the kinetics of HCV RNA levels.
As direct acting antivirals (DAA) have revolutionized hepatitis C treatment, they have also lead to new HCV RNA VL
result interpretations. Further, the clinical decisions were different for pegylated-interferon/ribavirin (PEGa/RBV)+
boceprevir or telaprevir-containing regimens approved in 2011 (e.g. one requiring an additional 4 week “lead-in”
with PEGa/RBV), each having different HCV RNA values for futility rules, created complexity in clinical decisions.
The future pegylated-interferon free DAA- regimens promise significantly improved cure rates along with fixed
durations and simpler treatment rules. The intent of this article is to discuss the role of HCV RNA real-time PCR
tests used in the management of CHC patients in the past and how this is likely to change in the era of interferon
free DAA regimens.
Background
Chronic HCV (CHC) infection is a global public-health
problem, with approximately 170 million persons chroni-
cally infected [1] who are at an increased risk of morbid-
ity and mortality [2] due to liver cirrhosis, hepatocellular
carcinoma (HCC), and extra-hepatic complications that
develop. The incidence of cirrhosis and HCC is projected
to dramatically increase over the next decade in certain
populations such as the U.S. “baby boomer” birth cohort.
With the development of interferon free, all oral,
potent antiviral agents with less adverse effects, the need
for screening individuals and successfully treating at-risk
CHC patients becomes increasingly more important and
possible.
New screening recommendations
The CDC has previously recommended routine HCV
screening for persons most likely infected with HCV
based on the known epidemiologic risk factors [2] and
has published guidelines for laboratory testing using
HCV antibody and HCV RNA assays [3]. In 2012, the
CDC amended testing recommendations to include one-
time HCV testing for all persons born between 1945
and 1965 ("baby boomers”) in the U.S. [3].
The new role for HCV RNA tests in the aid in
diagnosis of CHC patients
Screening for hepatitis C starts with anti-HCV antibody.
The OraQuick HCV Rapid Antibody Test (OraSure
Technologies) is a rapid assay for the presumptive
detection of HCV antibody in finger stick capillary
blood and venipuncture whole blood [4]. In the U.S.,
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this test is approved for use in doctor’s offices or clinics
that able to use laboratory-based IVD tests [3]. Rapid
tests are also available in Europe as well as other parts
of the world.
The Recombinant Immunoblot Assay (RIBA) HCV 3.0
Strip Immunoblot Assay (Novartis Vaccines and Diag-
nostics) that was previously recommended for supple-
mental testing of blood samples after initial HCV
antibody testing is no longer available or recommended.
In 2013, the recommendations were updated for supple-
mentary testing whereby the diagnosis of a current HCV
infection (a positive antibody test) should be confirmed by
using a NAT test (Figure 1). This is because an anti-HCV
antibody test result can be positive in patients who were
previously infected with HCV but have spontaneously
cleared infection and are no longer viremic. HCV RNA
tests can detect the presence of an active HCV infection.
In clinical practice guidelines, using a sensitive molecular
method (LLOD <15 IU/mL) is recommended for the diag-
nosis of acute hepatitis and CHC [4]. However, it’s impor-
tant to note that currently there are no real-time PCR
HCV RNA viral load monitoring tests that have been
reviewed or approved by any regulatory agencies, includ-
ing the FDA that have a diagnostic intended use claim
supporting these recommendations.
Significance of VL monitoring
Measurement of HCV RNA is essential for measuring an
active infection at baseline, during treatment, at the end
of treatment, and for detecting relapse after stopping
antiviral therapy (e.g. 12 or 24 weeks later). Absence of
viral replication as measured in the bloodstream 3 or 6
months after an antiviral treatment regimen indicates the
patient is cured.
Current molecular methods
A variety of molecular methods have been used to manage
CHC patients. The majority of tests that are used by rou-
tine clinical laboratories are based on real-time PCR tech-
nologies which quantify HCV RNA during the exponential
phase of amplification, with greater sensitivity and a
broader linear dynamic range (~10 to 108 IU/mL). There
are several HCV RNA commercial, real-time PCR tests
that are available (Table 1).
The COBAS® AmpliPrep / COBAS® TaqMan® HCV
Quantitative and Qualitative Test, version 2.0 (TaqMan®
HCV Test, v2.0) (Roche Molecular Systems) uses a mag-
netic silica bead-based automated RNA extraction on
the COBAS AmpliPrep platform followed by HCV tar-
get specific (5’ UTR) amplification and detection per-
formed on the COBAS TaqMan thermal cycler. The
assay is approved as a FDA-IVD and CE-IVD quantita-
tive test and as a CE-IVD qualitative test. Both the
quantitative and qualitative tests use a dual probe
approach where two fluorescently labeled hydrolysis
probes simultaneously detect amplicon, providing
broader detection and quantification of rare genotype 4
sequences [5,6]. HCV RNA titer is calculated using a
competitive quantitative standard, obviating the need for
the laboratory to perform calibrations. Reagents are
stored at 2-8oC. A manual version, the COBAS® Taq-
Man® Test v2.0 for use with the High Pure System (the
HP-TaqMan HCV, v2.0) (Roche Molecular Systems),
which instead uses a column-based manual extraction is
also available. This test has been predominantly used in
the clinical trials for currently approved DAA-interferon
containing regimens.
The Abbott RealTime HCV assay (Abbott Molecular)
uses an automated, magnetic particle-based nucleic acid
extraction on the m2000sp platform followed by a man-
ual sealing of the reaction plate to prepare it for HCV
target specific amplification and detection on the
m2000rt platform. To detect the HCV RNA target, a
DNA probe with a covalently linked fluorescent moiety
and a covalently linked quenching moiety is used. Since
a noncompetitive internal control (derived from a
pumpkin gene) is used, the laboratory is required to per-
form lot-specific calibrations. Reagents must be shipped
and stored frozen [7].
Figure 1 Centers for Disease Control and Prevention
recommendation: testing sequence for identifying hepatitis C
virus infection.
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The Versant HCV RNA 1.0 test (Siemens Healthcare)
is a real-time PCR assay that uses a magnetic silica
bead-based automated RNA extraction followed by
automated amplification of the HCV genome and detec-
tion on the Versant Kinetic PCR (kPCR) Molecular Sys-
tem platform. This test replaces the quantitative,
branched DNA (bDNA)-based, signal amplification test
as well as the qualitative TMA-based test [8].
The Artus Hepatitis C QS-RGQ assay is a real-time PCR
assay that uses a magnetic particle-based automated RNA
extraction on the QIAsymphony SP platform (Qiagen) fol-
lowed by amplification of the HCV genome and detection
on the Rotor-Gene Q platform [9].
Other molecular methods that are used in management
of CHC patients include genotyping tests (for HCV geno-
types 1-6), which help determine the type and duration of
treatment as well as to predict treatment outcomes. Cur-
rently, HCV genotyping tests use direct DNA sequencing
(e.g. THE TRUGENE® HCV Genotyping Assay, Siemens
Erlangen, Germany) and bi-directional sequences where
genotype and subtype characterization is determined by
two fluorescently labeled DNA primers or a line probe
assay (INNO-LiPA HCV II Genotype Test, Innogenetics,
Ghent, Belgium), that simultaneously detects of 5′UTR
and Core regions to improve genotype 1 characterization
using a linear probe array [10].
Several real-time PCR-based non-IVD Tests (e.g.
GenMark) are used and more recently the Abbott HCV
Genotype Test is currently available as the only FDA-
approved test. In a recent report, the Abbott HCV
Genotype Test (Abbott Molecular) has been found to
be useful for characterizing genotype 2-6 but may
require a confirmatory method for correct genotype 1
characterization [11,12]
Non-molecular methods
HCV core antigen serology tests have been proposed for
the use in either on-treatment monitoring or for assessing
SVR, but this application may miss approximately half of
the samples <2,000 IU/mL by PCR and may only be reli-
able in results >6,000 IU/mL [13]. Therefore, HCV core
antigen may not be suitable for detecting an active HCV
infection. Unlike HCV core antigen tests, the clinical uti-
lity of using HCV RNA PCR-based tests in managing
CHC patients is well established [14].
Treatment landscape; past, present, and future:
After a decade of using PEG2a/RBV to treat CHC patients,
boceprevir (VICTRELIS®, Merck & Co., Inc., Whitehouse
Station, NJ) and telaprevir (INCIVEK®, Vertex Pharmaceu-
ticals Incorporated Cambridge, MA), NS3/4A protease
inhibitors, co-administered with PEG2a/RBV were
approved for HCV genotype 1 infected patients in 2011
after demonstrating significant improvements in SVR rates.
Recently, at the end of 2013, two more drugs were
approved demonstrating even greater improvements in
SVR rates. Simeprevir (OLYSIO™, Janssen Therapeutics,
Titusville, NJ) a NS3/4A protease inhibitor [15,16] and
Sofosbuvir (SOVALDI™, Gilead Sciences, Inc., Foster City
CA) a potent HCV nucleotide analog NS5B polymerase
inhibitor are now available [15].
Simeprevir (plus PEG2a/RBV) was approved for HCV
genotype 1 infected subjects with compensated liver dis-
ease (including cirrhosis) along with a screening require-
ment for patients with HCV genotype 1a infections for
the presence of the NS3 Q80K polymorphism (in which
case this therapy is not recommended).
Sofosbuvir represents the first all oral, interferon free
DAA-containing regimen (combined with RBV) and the
first DAA-interferon-free regimen approved for treating
patients with HCV genotype 2 or 3 infections [17,18].
Sofosbuvir (plus RBV) has a shorter treatment duration
for genotype 2 (12 weeks) than genotype 3 (24 weeks).
HCV genotypes 1 or 4 infections can also be treated with
Table 1 Commercially available quantitative real-time PCR-based hepatitis C virus RNA assays











COBAS® TaqMan ® v2.0 Test
Roche Molecular
Systems
Real-time PCR, (5’UTR) FDA, CE 15 to
1.00 × 108
15 15
COBAS® TaqMan ® for use with the
High Pure System Test, v2.0
Roche Molecular
Systems
Real-time PCR, (5’UTR) FDA, CE 25 to
3.91 × 108
25 20
Abbott RealTime HCV Test Abbott Diagnostics Real-time PCR, (5’UTR) FDA, CE 12 to
1.00 × 108 [27]
12 12
Versant HCV RNA Test, 1.0 (kPCR) Siemens Real-time PCR, (pol gene) CE 15 to
1.00 × 108
15 15
Artus Hepatitis C Test (QS-RGQ) Qiagen Real-time PCR (target
proprietary)
CE 65 to
1 × 106 [9]
35 21
IVD: In vitro diagnostic. LLOQ: Lower limit of quantification. LLOD: Lower limit of detection (also referred to as analytical sensitivity). PCR: polymerase chain
reaction. FDA: Food and Drug Administration. CE: European Community. HCV: Hepatitis C virus.
* LLOD shown is the overall analytical sensitivity, the LLOD by genotype and by matrix (plasma vs. serum) may be lower than the number shown.
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sofosbuvir but require coadministration of PEGa/RBV
for 12 weeks.
The AASLD/IDSA recommendations for testing,
managing, and treating HCV were updated in 2014 in
response to the changing landscape of HCV treatment
options [19].
HCV RNA Test results & interpretations
A definition and description of terms used to describe
HCV RNA levels is provided (Table 2) and HCV RNA
VL results and interpretations are described (Table 3).
To note, if HCV RNA is detected by PCR (and lower
than the linear range of the test), the result is reported
by the software as “HCV RNA, detected less than the
Lower Limit of Quantitation (LLOQ)”, even if the actual
VL titer is below the sensitivity or Limit Of Detection
(LOD) of the test. Being able to “detect“ HCV RNA that
is below the LOD of the test may seem counterintuitive
since it is typically presumed that if the actual HCV
RNA titer is below the LOD then there is nothing there
to “detect“.
However, the LOD is defined and calculated by the
tests ability to detect HCV RNA ≥95% of the time. This
means that even at HCV RNA titers that are half the
LOD, the PCR amplification may still detect HCV RNA
~50% of the time, in which case, the result will be
reported as “HCV RNA detected, < LLOQ” if the HCV
RNA is “detected”.
Viral kinetics and RGT
In patients treated with PEGa/RBV, the best predictor
of an SVR was shown to be a rapid on-treatment HCV
RNA decline to “undetectable” early in therapy [20]. To
this end, a rapid virological response (RVR), or “unde-
tectable” (e.g. <50 IU/mL) by 4 weeks of PEGa/RBV,
has been used to determine eligibility for shortening
therapy (e.g. 24 weeks versus 48 weeks, genotype 1).
New definitions for an “undetectable” HCV RNA VL
While the goal of treating CHC patients is to eradicate the
infection as measured by an “undetectable” HCV RNA
result, “undetectable” has evolved alongside the treatment
algorithm. For PEGa/RBV therapy, an “undetectable”
result was any result that is <50 IU/mL (Table 4).
In contrast, for PEGa/RBV + boceprevir or telaprevir regi-
mens, the term “undetectable” was defined as a “target not
detected” result, which was required for patients to be
eligible for shorten therapy; but for SVR assessments, a
“<25 IU/mL, HCV RNA detected” was an acceptable
endpoint.
For the recently approved regimen containing simeprevir,
a stopping rule “cutoff” of 25 IU/mL is used at 4, 12, or 24
weeks in which all therapies are discontinued if HCV RNA
Table 2 Definitions of key analytical performance terms used in defining hepatitis C virus RNA VL titer measurements
based on guidelines [28]
Result Definition
Target not detect HCV RNA is not detected, no observable PCR amplification or detection
LLOQ Lowest HCV RNA titer within the test’s dynamic range that is quantifiable and accurate
LOD Lowest amount of analyte in a sample that can be detected (e.g. Detection of HCV RNA ≥95% by Hit Rate or PROBIT analysis)
ULOQ The highest HCV RNA titer result within the test’s dynamic range that is quantifiable and accurate
HCV: Hepatitis C virus. LLOQ: Lower limit of quantification, LOD: Limit of detection (also referred to as “analytical sensitivity”). ULOQ: Upper limit of quantification
Table 3 The results and interpretations that are reported by manufacturers of commercial hepatitis C virus RNA VL
tests
Titer result (IU/mL) Reported results Results interpretation*
“Target not detected” or
“Not detected”
Results are reported as “HCV RNA not
detected”.
Ct value for HCV is above the limit for the assay or no Ct value for HCV is
obtained.
Less than the Lower Limit
of Quantification (LLOQ)
Results are reported as “HCV RNA
detected, less than [LLOQ] IU/mL HCV
RNA”.
Calculated IU/mL is below the dynamic range of the assay.
Titer is within the linear
range of the test
Results are reported as “[number]
IU/mL, HCV RNA detected”.
Calculated results are quantifiable within the dynamic range of the test (e.
g.greater than or equal to the LLOQ and less than or equal to ULOQ,
results)
Greater than the upper
limit of quantification
(ULOQ)
Results are reported as “greater than
[ULOQ] IU/mL HCV RNA”.
Calculated results are above the dynamic range of the assay.
* Ct = crossing point or crossing threshold, the value in which the PCR amplification is detected (sigmoidal curve)
HCV: Hepatitis C virus. LLOQ: Lower limit of quantification. ULOQ: Upper limit of quantification.
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results are above this cutoff (Table 4). For sofosbuvir, HCV
RNA testing is only recommended after treatment after a
fixed duration and to assess SVR. Both regimens use “<25
IU/mL, HCV RNA detected” for defining “undetectable”.
In the “real world setting” it is likely that there will be
less patient compliance than in the clinical trials. There-
fore, it may be useful to investigate whether HCV RNA
VL “adherence monitoring” on-therapy is worthwhile in
patients suspected of noncompliance, especially when
considering the high treatment costs.
Given that the trials used a test with a LLOQ of 25
IU/mL, differences in a tests LLoQ is important. How
should clinicians handle a quantifiable result of 22 IU/
mL derived from a different test than the one used in
the clinical trials (e.g. one that has a lower LLOQ)?
These are practical considerations that may cause uncer-
tainty for clinicians.
Using “target not detected” for shortening therapy
With the introduction of boceprevir and telaprevir, new
RGT rules were introduced which lead to considerable
confusion in the terms used to define “undetectable”
and when to apply this interpretation. These rules were
based on a re-analysis of the boceprevir and telaprevir
trials data that was published by the FDA where it was
concluded that a “HCV RNA detectable, <LLOQ” result
predicted a significantly lower cure rate compared with
subjects with an “undetectable” ("Target Not Detected”)
result [21]. Based on this analysis, it was determined
that a confirmed “detectable but below the LLOQ” HCV
RNA result should not be considered equivalent to an
“undetectable” HCV RNA ("Target Not Detected”) result
for the purposes of RGT. Therefore, a “Target Not
Detected” result at both 4 and 12 weeks of PEGa/RBV +
telaprevir therapy was required to shorten therapy (48
weeks to 24 or 36 weeks of PEGa/RBV). To further add
complexity, stopping rules were also different for bocepre-
vir and telaprevir regimens (100 and 1,000 IU/mL,
respectively).
Differences between HCV RNA assays with DAA therapies
Although all commonly used HCV RNA assays report the
results in the standardized IU/mL, not all tests perform
similarly. Several reports have demonstrated differences
between how assays report results, particularly in detecting
low amounts of HCV RNA [22,23].
In these studies, concordance analyses have deter-
mined that HCV RNA differences in reporting results
that are “Target Not Detected” versus “HCV RNA
detected, < LLOQ” have become apparent.
This is particularly true in one study that investigated
results generated from the TaqMan ® HCV Test, v2.0
used as part of a phase III clinical trial with simeprevir
plus PEGa/RBV and compared it to Abbott RealTime
HCV Test [24]. Overall, there was good agreement
between the 2 assays; however, a large number of samples
(26%-35%) at week 4 of treatment had detectable HCV
RNA levels (<LLOQ) with the Abbott RealTime assay that
were “Target Not Detected” by the HPS-TaqMan ® HCV
Test, v2.0. These patients received shortened therapy
based on the HPS-TaqMan ® HCV Test, v2.0 TND result
and high SVR rates were achieved. Thus, if the Abbott





Response guided therapy Definition of “undetectable” HCV












1-6 YES 4 or 12 week 4, (RVR) <50 IU/mL or week 12,
(partial responder) 2 log10 drop
















1 N/A N/A N/A 12 < 25
SOF/RBV 2, 3 N/A N/A N/A 12 or 24 < 25
* Fixed duration regimen, HCV RNA VL ≥25 IU/mL is a stopping rule.
** with a 4 week lead-in (PEGa/RBV)
† The test used was the COBAS® TaqMan® for Use with the High Pure System (LLOQ = 25 IU/mL, overall LOD = 20 IU/mL)
HCV: Hepatitis C virus. SVR: Sustained virologic response. PEGa: Pegylated interferon alpha. RBV: ribavirin. RVR: Rapid virological response. TVR: Telaprevir. TND:
Target not detected. RGT: Response guided therapy. BOC: boceprevir. SIM: Simeprevir. SOF: Sofosbuvir.
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RealTime assay results at week 4 of therapy had been used
to determine treatment duration, these patients may have
been over-treated by an additional 6 months.
Since these DAA-containing triple therapy requires
HCV RNA to be TND at both weeks 4 and 12 in order to
shorten therapy, differences between HCV RNA assays
can affect key medical decisions, in this case resulting in
a larger portion of patients treated for longer durations
(if the same cutoffs are used). It was therefore suggested
that a cutoff of <12 IU/mL (detected) may be appropriate
for the Abbott RealTime HCV Test. However, since this
cutoff has not yet been clinically validated and further
studies are needed.
While boceprevir and telaprevir containing regimens
have been replaced by more potent regimens, differences
in the performance of HCV RNA tests might be of impor-
tance, particularly if they are not clinically validated.
Therapies expected in the near future
Faldaprevir is a HCV protease inhibitor in late stage
phase 3 clinical trials and administered once daily is
being tested in combination with PEGa/RBV, and in
IFN-free regimens with other DAA agents.
Sofosbuvir is also being investigated in combination
with antiviral agents that target different virus proteins
such as daclatasvir and ledipasvir (nonstructural protein
5A [NS5A] inhibitors), with or without RBV [25]. Preli-
minary results of Phase 3 trials of the interferon-free
sofosbuvir and ledipasvir combination regimen in
patients with HCV genotype 1 infection have shown
SVR12 rates of 93%-99% (Table 5).
Abbvie is evaluating an interferon-free 3-DAA combi-
nation regimen containing the ABT-450, ritonavir, and
ABT-267 co-formulated tablet (ABT-450/r/ABT-267)
and ABT-333 tablet administered with or without RBV.
ABT-450 is a NS3A protease inhibitor; ABT-267 is a
NS5A inhibitor; and ABT-333 is a non-nucleoside inhi-
bitor of the NS5B polymerase. This 3-DAAs regimen
with and without RBV has reported SVR12 rates of
90%-100% in a phase 2 trial of patients infected with
HCV genotype 1 [26]. Preliminary results of Phase 3
trials of this 3-DAA regimen have shown very high
SVR12 across different HCV genotype 1 infected patient
populations (Table 6).
Table 5 Summary of phase 3 trials of sofosbuvir and ledipasvir in hepatitis C virus genotype 1
Study Population Treatment/Duration SVR12 rates
ION-1 HCV GT1 treatment-naïve including 15.7% (136/865) with cirrhosis SOF/LDV, 12 weeks 97.7% (209/214)
SOF/LDV + RBV, 12 weeks 97.2% (211/217)
SOF/LDV, 24 weeks NA (n = 217)
SOF/LDV + RBV, 24 weeks NA (n = 217)
ION-2 HCV GT 1 treatment-experienced including 20.0% (88/440) with cirrhosis SOF/LDV, 12 weeks 93.6% (102/109)
SOF/LDV+RBV, 12 weeks 96.4% (107/111)
SOF/LDV, 24 weeks 99.1% (108/109)
SOF/LDV+RBV, 24 weeks 99.1% (110/111)
ION-3 HCV GT1 treatment-naïve SOF/LDV, 8 weeks 94.0% (202/215)
SOF/LDV + RBV, 8 weeks 93.1% (201/216)
SOF/LDV, 12 weeks 95.4% (206/216)
SVR: Sustained virologic response. HCV: Hepatitis C virus. GT: Genotype. SOF: Sofosbuvir. LDV: ledipasvir. RBV: ribavirin. NA: not available.
Table 6 Summary of phase 3 trials of ABT-450/r/ABT-267, ABT-333 plus ribavirin in hepatitis C virus genotype 1
Study Population Treatment/Duration SVR12
PEARL-II GT1b treatment-experienced (N = 179) 3-DAA + RBV, 12 weeks (n = 88) 97%(85/88)
3-DAA only, 12 weeks (n = 91) 100% (91/91)
PEARL-III GT1b treatment-naive (N = 419) 3-DAA + RBV, 12 weeks (n = 210) 99% (209/210)
3-DAA only, 12 weeks (n = 209) 99% (207/209)
PEARL-IV GT1a treatment-naive (N = 305) 3-DAA + RBV, 12 weeks (n = 100) 97% (97/100)
3-DAA only, 12 weeks (n = 205) 90% (185/205)
TURQUOISE-II GT1 treatment-naive and treatment-experienced with
compensated cirrhosis (N = 380)
3-DAA + RBV, 12 weeks (n = 208) 92% (191/208)
3-DAA + RBV, 24 weeks (n = 172) 96% (165/172)
SAPPHIRE-I GT1 treatment-naive (N = 631) 3-DAA + RBV, 12 weeks (n = 473) 96% (455/473)
SAPPHIRE-II GT1 treatment-experienced (N = 394) 3-DAA + RBV, 12 weeks (n = 297) 96% (286/297)
SVR: Sustained virologic response. GT: Genotype. DAA: Direct acting antivirals. RBV: ribavirin.
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Future directions
Given the global burden of CHC and the advent of
newer, more potent regimens with higher cure rates,
increasing screening to identify at-risk CHC patients
and linking them to care is even more important. New
guidelines that support screening are important but
linkage to care is an ongoing global challenge.
With the first DAA-containing regimens, clinical deci-
sions based on HCV RNA VL results (and new interpre-
tations) created complexity for the laboratory and
clinician. Further, tests were shown to perform differ-
ently in some of DAA-containing regimens. Therefore,
additional testing with each new DAA containing regi-
men across various commercially available HCV RNA
tests is important.
While the new interferon-free therapies have demon-
strated greater efficacy, accurate HCV RNA quantifica-
tion remains important. In addition, interferon-free
regimens may have fixed durations, but on-therapy
“adherence monitoring” may be helpful, particularly
given the high cost of the new regimens. Therefore, for
these and other reasons discussed here, measuring HCV
RNA will likely continue to be important.
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